Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $5.83 Average PT from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $5.8333.

Several brokerages have commented on ZNTL. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Tuesday, April 7th. Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price target for the company. Guggenheim lifted their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Finally, Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $4.46 on Friday. The company has a market capitalization of $317.51 million, a PE ratio of -2.58 and a beta of 1.92. The business has a fifty day moving average price of $3.97 and a two-hundred day moving average price of $3.11. Zentalis Pharmaceuticals has a 1 year low of $1.15 and a 1 year high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Sell-side analysts anticipate that Zentalis Pharmaceuticals will post -1.92 earnings per share for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. CTC Alternative Strategies Ltd. purchased a new position in shares of Zentalis Pharmaceuticals during the 1st quarter valued at $29,000. Invesco Ltd. increased its holdings in Zentalis Pharmaceuticals by 8.6% in the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock worth $255,000 after acquiring an additional 14,961 shares during the last quarter. Barr E S & Co. increased its holdings in Zentalis Pharmaceuticals by 43.8% in the 4th quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock worth $78,000 after acquiring an additional 17,500 shares during the last quarter. Vanguard Group Inc. raised its stake in Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after acquiring an additional 19,768 shares during the period. Finally, Sivia Capital Partners LLC bought a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at about $27,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.